Inhibition assays were used to investigate human serum antibodies to the meningococcal class 1 outer membrane proteins. We adapted the whole-cell enzyme-linked immunosorbent assay technique to determine the ability of sera to inhibit the binding of murine subtyping monoclonal antibodies. Serum samples from 33 South African subjects with a deficiency in the sixth component of complement as well as serum samples from various groups of complement-sufficient subjects were investigated. Subjects were subdivided according to whether they were (i) convalescent from Neisseria meningitidis infections, (ii) nonconvalescent, or (iii) controls.
recognized by the murine monoclonal antibodies and raises the possibility of the importance of other epitopes.
Neisseria meningitidis infections frequently result in lifethreatening meningitis and/or bacteremia. In immunocompetent individuals, the disease seldom occurs more than once. Goldschneider et al. (8) presented convincing evidence of the role of bactericidal antibodies in preventing the development of the disease, although the role of opsonic antibodies in protection against meningococcal disease requires further investigation (6) . The situation in individuals who have defects in the complement system, particularly of the terminal complement pathway, is somewhat different. These individuals frequently suffer recurrent infections, and the role that antibodies play both in eliminating the infections and in protecting subjects from further infections is still uncertain.
In the Western Cape Province, South Africa, meningococcal infections are endemic, with an incidence of approximately 20 cases per 100,000 population per year, rising to about 100 cases per 100,000 per year in epidemic periods (15) . A relatively large number of individuals with a genetic deficiency of the sixth complement component (C6D) have been diagnosed within this area, and many of the affected subjects suffered recurrent meningococcal infections (13) . Preliminary data showed that some patients did develop antibodies to meningococcal outer membrane proteins (OMP), but the specificity of these antibodies was not investigated (15) . Studies of serum antibodies in American complement-deficient subjects also confirmed the presence of potentially bactericidal and opsonic antibodies (4 likely components of a meningococcal vaccine (16, 18) . The class 1 proteins are porin proteins present on almost all meningococcal isolates (14) , and antigenic diversity is limited and allows subtyping classification (2) . Cloning and sequencing the genes for the class 1 proteins (3) have led to deduction of the amino acid sequences of four different strains (11, 18) . Models for class 1 and other porins predict eight surface-exposed regions or loops, of which loops 1 and 4 are the most accessible in class 1 (18) . Differences in the amino acid sequences between subtypes are mostly confined to the two variable regions coding for these loops. Epitope analysis with the relevant murine monoclonal antibodies (MAbs) showed that the anti-P1.7 MAb reacted with peptides from loop 1 of the P1.7 strain and the anti-P1. 16 and anti-P1. 15 MAbs reacted with peptides from loop 4 of the relevant strains (11) . The epitope for an anti-P1.2 MAb has now been ascribed to loop 4 (18) . The epitope for P1.4 is also believed to be within loop 4, since many P1.4 strains also express the loop 1 P1.7 epitope.
Murine MAbs are tools developed to recognize subtype differences, and their specificities will not necessarily be reflected by human anti-class 1 antibodies. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) studies combined with electroblotting (19) have shown the presence of anti-class 1 antibodies in immune sera, but this method does not allow any determination of epitope specificity. To address this problem, Mandrell and Zollinger (10) developed an inhibition enzyme-linked immunosorbent assay (ELISA) and showed that the majority of serum samples from convalescent patients were able to inhibit the binding of appropriate subtyping MAbs to OMP preparations from the patient's own infecting meningococcal strains. Neverthe- Fig. 2 ), but it was only used as a standard for calculation of human antibody levels from the inhibition of the anti-P1.2 MAb MN2B6G. The standard was arbitrarily ascribed as having 100 U of anti-class 1 antibody, and levels in the other sera were determined relative to this standard serum. A standard curve was set up for every plate, with four duplicate dilutions of the standard serum. The duplicate results for the dilution of the unknown that produced inhibition that fell within the midrange of the standard curve were used for calculating the units of antibody present in the unknown. This calculation automatically adjusted the results for interplate variation and adjusted for the nonlinear inhibition curves at high antibody concentrations (see Fig. 1 ). A control serum that was obtained from an individual with no history of clinical meningococcal infection and that produced low inhibition was also run on each plate.
Subjects. The subjects investigated were divided into eight groups according to their serum complement activity and clinical and epidemiological criteria ( Table 2 ). All C6D subjects were discovered by meningococcal disease in themselves or in an immediate family member. The absence of the sixth complement component was diagnosed by means of a functional hemolytic assay described previously (9, 13) . The C6D subjects were subdivided into convalescent, nonconvalescent (no clinical infection within the past year), and never clinically infected (groups 1, 2, and 3, respectively; Table 2 ). As meningococcal infection tends to occur at a later age in complement-deficient than in normal individuals (13) , and as age may be related to immune responsiveness (15), we excluded data for all children who were less than 5 years old. Convalescence was taken as the period from 14 to 65 days after admission for the acute episode. This wide period was used for both the deficient group 1 patients and the sufficient group 5 patients. It was necessary because the deficient subjects were usually referred to the study after discharge from the hospital. Approximately 85% of the C6D subjects and the complement-sufficient group 5 and group 6 subjects were Cape coloreds (of mixed caucasoid, southeast Asian, and southern African [Hottentot] extraction); however, a few were Xhosa-speaking black Africans. The group of control African blood donors (group 7) were all black Africans, and the group of healthy British laboratory workers (group 8) were all caucasoid. For the purposes of the statistical analyses, any individual subject was investigated only once, and any C6D patient for whom we had a convalescent sample was investigated in group 1. Laboratory diagnosis of meningococcal disease was made by cerebrospinal fluid or blood culture and occasionally by microscopy only. The complement-deficient patients were Meningococcal isolates. This study includes results from antibody studies on serum samples taken during convalescence from 40 episodes of meningococcal infection. The complement-deficient patients had nearly all also suffered earlier episodes, but information on the current episode only is included here. The complement-sufficient patients all suffered primary infection.
Polysaccharide antigen grouping was performed at the South African Institute of Medical Research for 20 isolates. The results for isolates from 10 complement-deficient subjects were one group A and nine group B, and the results for 10 isolates from the complement-sufficient patients were three group A, three group B, and four group C.
Three South African isolates that had been sero-subtyped at the Netherlands Meningococcal Reference Laboratory (B:nt:Pl.2; B:4:P1.15; and B:nt:Pl.16,P1.7) were used to sensitize plates for anti-P1.2, anti-P1.16, anti-P1.7, and anti-P1.15 ELISAs, and strain 882066 (B:nt:P1.4), which was received from Bilthoven, was used for the anti-P1.4 assay.
Statistical tests. Although results are expressed as units, the level of measurement is only ordinal, and therefore the nonparametric Mann-Whitney U test was used to compare antibody levels (17) .
RESULTS
The initial experiments for the study were carried out with the anti-P1.2 MAbs MN4C5E and MN2B6G (Table 1) in order to identify sera with anti-class 1 P1.2 antibodies. Forty-eight serum samples representative of subjects in the various groups were screened in this way, and inhibitory activity was found in a number of them. The inhibition patterns produced by three serum samples from one C6D case are illustrated in Fig. 1 . The samples were taken 3 weeks, 9 weeks, and 3 years after her second meningococcal infection, and this infection was with a B:nt:P1.2 organism. She was 19 years old at the time of infection. The figure illustrates that the convalescent specimen had strong inhibitory activity for both MAbs, with stronger inhibition for MN4C5E than for MN2B6G. By 9 weeks postadmission, the inhibitory activity was very much lower and had disappeared 3 years later. Results for the control serum from plates run on different days showed up to 20% inhibition of MAb binding, and therefore up to 20% inhibition was considered as indicating that no relevant antibodies could be detected. The mean (range) inhibition of MN2B6G by the control group 6 sera at concentrations of 0.05 was 10% (5 to 16%).
In order to investigate whether the inhibition observed was specific for the binding of the MAbs to P1.2 epitopes, we tested the majority of the 48 serum samples for their ability to inhibit three other MAbs directed at the epitopes P1.4, P1.15, and P1.16 within the loop 4 region of the class 1 OMP and one MAb directed against P1.7, an epitope within the loop 1 region. The results for some of these serum samples, tested at a final serum dilution of 0.05, are shown in Fig. 2 . Figure 2A shows the percent inhibition of MAb binding brought about by serum samples from representative group 1 subjects (C6D patients convalescing from meningococcal disease), Fig. 2B shows the results for C6D patients who had either suffered infection more than a year previously (group 2) or had never suffered clinical meningococcal disease (group 3), and With almost all of the positive sera, the highest inhibition was produced in assays with the anti-P1.2 MAb MN4C5E. Inhibition of the other anti-P1.2 antibody, MN2B6G, tended to be very similar to the inhibition of the anti-P1. 4 of complement-deficient subjects (n = 29); group 5, South known of the biological role of these antibodies. The study of 'mplement-sufficient convalescent subjects (n = 20); group the functional relevance of antibodies in this situation would African controls (n = 13); group 7, black African blood be greatly facilitated by determination of the antibody spec-= 13); Group 8, healthy British laboratory workers (n = ificities.
-s and median antibody levels are given in Table 2 . Group We commenced the study with investigations of human had the highest antibody levels; these were significantly anti-P1.2 antibodies, and as shown in Fig. 1 , the assays ni those found in group 4 (P < 0.01), group 5 (P < 0.01), or measured infection-related antibodies. However, the results < 0.01) subjects and highly significantly higher than those inaigr2dieontraeatse antibodies. caples and group 8 subjects (P < 0.001) (Mann-Whitney U test).
in Fig. 2 demonstrate that sera containing antibodies capable group 1 subjects had only marginally higher levels than of inhibiting the anti-P1.2 MAbs were also capable of inhibionconvalescent, deficient) subjects (P < 0.05). Group S iting MAbs directed against other loop 4 region antigens.
ad significantly higher levels than either group 6 or group Results obtained with the anti-P1.4 MAb MN2OB9.34 (P < 0.01), but there was no significant difference showed a particularly strong correlation with the results he levels in group 5 and group 7 subjects. There were only obtained with the anti-P1.2 MAbs. Subtyping studies of -cts in group 3, and therefore their results were not approximately 140 isolates from the Cape have failed to find any carrying the P1.4 antigen (12), and therefore it appears extremely unlikely that the ability of the sera from the Cape subjects to inhibit the anti-P1.4 MAb arises from antibodies induced by exposure to the P1.4 antigen itself. We consider 1r to investigate the levels of anti-class 14 antibodies it probable that the close correlation of the inhibition of the samples from the various groups of subjects desig-MN2B6G and MN2OB9.34 indicates that human antibodies ove, we took the inhibition of the anti-P1.2 MAb recognize antigens that are spatially close to, but not iden-J as being representative. We determined the ability tical to, the epitopes recognized by these two MAbs. Obvisera to inhibit MN2B6G, with the assay being ously, the specificities of these human antibodies may differ ized with serum from a C6D patient. The antibody in different sera, and it may be that some are induced by e expressed in units, calculated as described in infections with other organisms, such as nonpathogenic and Methods. The standardizing serum, from neisseriae. Estabrook and coworkers (5), using similar inhir, as well as inhibiting MN2B6G and MN4C5E, was bition assays, were able to define meningococcal lipoolito inhibit the anti-P1.15, -P1.16, and -P1. 4 P1.7 is located within the loop 1 region, and therefore antibodies that inhibit MAb binding to loop 4 region epitopes are unlikely to inhibit the anti-P1.7 MAb, and this may account for the poor correlation between MN2B6G inhibition and MN14C11.6 inhibition. However, specific antibodies were not purified from the human sera, and whole sera with anti-class 14 antibodies are likely to also contain antibodies directed towards the loop 1 region.
We studied anti-class 14 antibodies in a number of sera from C6D and complement-sufficient patients who had suffered meningococcal infection. Figure 3 shows the results of anti-class 1i antibodies in the various groups of subjects. Convalescing C6D patients (group 1) tended to have the highest antibody levels and also had a very wide range of levels. For all except one of the patients, the relevant infection was a recurrent infection, which may explain why levels were significantly (P < 0.01) higher than found in the complement-sufficient convalescing patients (group 5); however, other factors, such as increased time of exposure to the organisms or differences in antigen processing, may play a role. The convalescent complement-sufficient patients (group 5) did have significantly (P < 0.01) raised levels compared with the control subjects (group 6). High levels were found in certain nonconvalescing deficient patients (group 2) and nondeficient immediate-family members (group 4), and this may indicate repeated or recent exposure to antibody-inducing organisms. The inhibition results illustrated in Fig. 2B show that deficient subjects who have already suffered recurrent disease can develop markedly increased antibody activity without the development of clinical disease. The African adult blood donor controls (group 7) had levels that were not statistically different from those of convalescent sufficient patients (group 5). Socioeconomic factors probably led to exposure to organisms that induced the high antibody levels. Unfortunately, we had no serum samples taken prior to the development of infection, but comparing the antibody results for groups 1, 2, and 5 with the low levels found in group 6 strongly suggests that the antibodies were infection induced.
The tendency to relapse has been reported for United States terminal complement component-deficient subjects (6) , and although the Cape patients did not have overt relapses, some maintained very high antibody levels for several years. This would be most easily explained by continuous or repeated exposure to relevant antigens. The rapid decline in antibodies following recovery of the subject illustrated in Fig. 1 reinforces our concern as to the cause of these high antibody levels. The benzathine penicillin that high-risk susceptible subjects receive as prophylaxis (15) against recurrent clinical disease would not be particularly efficient in eliminating foci of infection from the nasopharynx. It may therefore be wise to use a course of rifampin or ciprofloxacin treatment to eliminate organisms from the subjects and their immediate family.
Further investigations are required on a number of aspects of this study. As outlined above, more direct measurements of the specificities of the antibodies are required to determine the important meningococcal epitopes for vaccine production. If the epitopes recognized by human antibodies are indeed less diverse than the subtyping epitopes, this may have important implications for vaccine production. Another question of importance to vaccine production is the duration of the antibody response. The indications from the data illustrated in Fig. 1 are that high antibody levels are not naturally maintained after recovery, and if the anti-class 14 measured here prove to be protective in normal individuals, it would obviously be beneficial to prolong the response. Unfortunately, we had few such sets of sequential samples, but we hope to extend this section of the study. Further investigations of the role of nonpathogenic neisseriae in inducing protective immunity might also be fruitful. The important question that we have not yet answered in this study is whether the antibodies we detect are either bactericidal or opsonic. Another corollary that we wish to address is the possible role of antibodies of various specificities in protecting individuals with complement deficiency from further meningococcal infection.
